Definitive Contract 75N91020C00029
Award Date
9/8/20
Potential Completion Date
6/7/21
Potential Value
$398K
Federal Agency
National Cancer Institute
Awardee
Ferrologix Inc.
Ultimate Awardee
Not listed
NAICS Category
541713 - Research and Development in Nanotechnology
Federal Contract Vehicle
Set-Aside Type
Total Small Business
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
La Costa, CA 92011, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
6
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed
Research Type
SBIR Program Phase I Action
Primary Consortia Member
Not listed
Similar Awards
This contract was awarded by the Department of Health and Human Services' National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases to Ferrologix Inc., a small disadvantaged business, to provide research, development, and production services related to a sample sparring assay for isolation and analysis of immune cell populations using magnetic ratcheting. The firm fixed price contract has a potential value of $149,931.00 and was completed on August 31, 2020....
This is a $399,062 firm-fixed-price SBIR Phase I contract awarded by the National Cancer Institute (NCI) to Avoneaux Medical Institute, LLC for the development of spatial micro-purification technology. The contract was set aside for small businesses and is part of the NCI's broader SBIR program, which funds research and development in support of the NIH and CDC's mission needs. The original solicitation sought proposals on a range of cancer-related topics, including alternatives to cell...
This is a $355,000.00 Firm Fixed Price definitive contract awarded by the National Cancer Institute (NCI), a civilian agency within the U.S. Department of Health and Human Services, to Immunotarget Therapeutics Inc., a woman-owned small business. The contract is for the NCI's Small Business Innovation Research (SBIR) Innovative Concept Award program, which seeks proposals for highly innovative therapies, diagnostic tools, or preventive strategies focused on pediatric and/or rare cancers. The...
This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a civilian agency, to Nvigen, Inc., a small disadvantaged business and woman-owned manufacturer. The contract is for the development of cell-free tumor DNA (ctDNA) diagnostic enabled by magnetic automation assays, under SBIR Topic 353. The contract has a firm fixed price of $275,261.00 and a completion date of August 18, 2017. The contract does not utilize a set-aside...
<p>This is a $299,999.00 Firm Fixed Price contract awarded by the National Cancer Institute, a civilian agency, to Innogenomics Technologies, L.L.C., a minority-owned small business, under the Small Business Innovation Research (SBIR) Program Phase I. The contract is for research and development in the area of biomedical (basic research). It was awarded on September 22, 2015 with a final completion date of March 21, 2017. The contract has a total small business set-aside designation.</p>
This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), to Celartia, Inc., a small disadvantaged business, for the development of a fully automated system for cell therapy processing. The contract has a period of performance from September 13, 2021 to June 12, 2022 and a ceiling value of $393,312. The contract was awarded under a total small business set-aside. The original...
This SBIR Phase I contract was awarded by the National Institutes of Health's National Cancer Institute to Cellfe Inc. for $358,930. The contract is for the period of September 8, 2020 through June 7, 2021 and involves research and development of a microfluidic transfection platform for rapid manufacturing of mRNA CAR lymphocyte products. The solicitation sought proposals to conduct R&D in support of NIH and CDC agency missions, including alternatives to cell culture materials and cancer...
This is a $198,641 Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI) to Nanocellect Biomedical Inc., a for-profit biotechnology company. The contract is for the development of a "CTC Label and Capture by Lab-on-a-Chip Flow-Cytometry" solution, which aligns with the NCI's research interests. Nanocellect Biomedical is an innovative provider of automated cell analysis, sorting, and dispensing equipment and services, with a strong...
<p>This is a federal contract awarded by the National Cancer Institute, a civilian agency, to Transgenex Nanobiotech Inc., a minority-owned small business. The contract, valued at $224,999.00, is for a Small Business Innovation Research (SBIR) Program Phase I action. The contract is a definitive, firm-fixed-price contract with a completion date of September 15, 2015. This contract is set aside for small businesses.</p>
This is a $1,997,803 firm fixed-price definitive contract awarded by the National Cancer Institute (NCI), a civilian agency within the Department of Health and Human Services, to Cell Microsystems Inc., a small business manufacturer of specialized biomedical research equipment and tools. The contract is for the topic "Integrated Imaging and Molecular Analysis of Glioblastoma Using SCOPE SEQ on the Air Flow" and has a total small business set-aside designation. The contract will support...